Darunavir.JPG

Darunavir

CLINICAL USE

Protease inhibitor:Treatment of HIV infection with 100 mg of ritonavir, in combination with other antiretroviral medication

DOSE IN NORMAL RENAL FUNCTION

600 mg twice daily

PHARMACOKINETICS

  • Molecular weight                           :593.7 (as ethanolate)
  • %Protein binding                           :95
  • %Excreted unchanged in urine     : 7.7
  • Volume of distribution (L/kg)       :29.1–147.1 litres (81.1–180.9 litres with ritonavir)
  • half-life – normal/ESRD (hrs)      :15 (with ritonavir)/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unlikely to be dialysed. Dose as in normal renal function
  • HD                     :Unlikely to be dialysed. Dose as in normal renal function
  • HDF/high flux   :Unlikely to be dialysed. Dose as in normal renal function
  • CAV/VVHD      :Unlikely to be dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsAntibacterials: rifabutin concentration increased – reduce dose of rifabutin; darunavir concentration reduced by rifampicin – avoid concomitant useAntidepressants: possibly reduced concentration of paroxetine and sertraline; darunavir concentration reduced by St John’s wort – avoid concomitant use

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments